[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584348":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":27,"locations":33,"responsibleParty":51,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Azienda Ospedaliero-Universitaria di Parma","OTHER",[8,13,16,19],{"label":9,"type":6,"description":10,"interventionNames":11},"Participants in the OPCT study - MT 'A', low disposition index (n=10)",null,[12],"Other: Study setting",{"label":14,"type":6,"description":10,"interventionNames":15},"Participants in the OPCT study - MT 'A', high disposition index (n=10)",[12],{"label":17,"type":6,"description":10,"interventionNames":18},"Participants of the OPCT study - MT 'B', low disposition index (n=10)",[12],{"label":20,"type":6,"description":10,"interventionNames":21},"Participants of the OPCT study - MT 'B', high disposition index (n=10)",[12],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Study setting","The subjects in the study will undergo two days of visits, in random order.\n\n1. Following a fasting period of at least 4 hours, the study participants will undergo a PET-CT examination with Ga-exadin-4. Fasting will reduce the endogenous secretion of GLP-1 by the small intestine, which can otherwise compete with exendin-4 for binding to GLP-1R. Blood glucose will be measured before the injection of the tracer and monitored at each time point.\n2. On a fasting basis, the anthropometric data of the enrolled subjects will be collected and they will undergo a short interview on their lifestyle. Subsequently, at time 0, the subjects will ingest a standard mixed meal consisting of 2 commercially available \"ABC Parmareggio\" snacks. Venous blood samples will be taken at specific time intervals (from -20 to 300 minutes) to measure glucose, C-peptide, insulin, glucagon, GLP-1 and glucose-dependent insulinotropic (GIP) curves. An additional blood sample will be taken at time -10 in order to isolate",[14,9,20,17],[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Alessandra Dei Cas, Prof.","CONTACT","+390521033321","alessandra.deicas@unipr.it",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Parma","PR","Italy","IT",{"type":41,"coordinates":42},"Point",[43,44],10.32618,44.79935,{"lat":44,"lon":43},[47,48],{"name":29,"role":30,"phone":10,"phoneExt":10,"email":32},{"name":49,"role":30,"phone":10,"phoneExt":10,"email":50},"Raffaella Aldigeri, Dr","raffaella.aldigeri@unipr.it",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Alessandra Dei Cas","Prof.",[56],{"name":57,"class":6},"University of Parma","100584348","food-polyphenol-metabotypes-and-beta-cell-mass-and-function-100584348",false,"NCT06888167","Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.","Experimental, Drug-free, Cross-sectional, Single-centre Study to Assess the Association Between Metabotypes of Dietary (Poly)Phenols and Beta-cell Mass and Function.","META-BETA","Inclusion Criteria:\n\n* Having been enrolled in the OPCT study;\n* Ability to understand the methods, purposes and implications of the study, and to give free and informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Previous exposure to ionizing radiation in research programs;\n* History of psychiatric illness or alcohol abuse;\n* Head trauma;\n* Active neurological disease;\n* Claustrophobia;\n* Active malignant neoplastic disease.",true,"ALL","18 Years",{"count":70,"type":71},40,"ESTIMATED","INTERVENTIONAL",[74],"NA","Cross-sectional, single-centre, 'low intervention' clinical study, without drug or medical device testing, with low-risk diagnostic technique.",[77],"Healthy Volunteer","2025-03-14",{"date":80,"type":81},"2025-03-21","ACTUAL",{"date":83,"type":81},"2024-10-14",{"date":85,"type":71},"2026-02-28",{"name":5,"class":6},1]